Jamie is a partner with a biochemistry background and over 12 years’ of patent experience in the life sciences field. Jamie's practice includes biopharmaceuticals, diagnostics and synthetic biology. He has particular experience in the field of cell and gene therapy, including, for example, CRISPR (and other gene editing techniques), AAV vectors, CAR-T, and stem cells.
In addition to handling the drafting and prosecution of patent applications, Jamie has a strong opposition practice and has been involved in some of the most commercially important and legally complex oppositions in the life sciences field at the European Patent Office (EPO), relating to, for example, high value antibody, fusion protein, formulation and CAR-T patents.
Another significant part of Jamie’s practice is designing and advising on freedom to operate (FTO) strategies to suit a range of budgets and commercial requirements. He also has extensive experience of coordinating FTO efforts across multiple jurisdictions, with strong connections to local counsel in key locations.
Outside of Jamie’s day-to-day client work, Jamie had the privilege of presenting to a WHO Expert Advisory Committee on patents and human genome editing as part of the Committee’s consultation process, which led to the publication in July 2021 of the first global recommendations on governance mechanisms for human genome editing. He also provides regular lectures on intellectual property for biochemical engineers at University College London, and for King’s College London on their cell therapy MSc course.
Jamie graduated from the University of Bristol with a first class degree in biochemistry, which included modules in pharmacology, chemistry and the molecular basis of diseases.